BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 4, 2008
View Archived Issues
Denosumab Builds Bone Density, but Infection Concerns Emerge
Amgen Inc.'s experimental osteoporosis drug, denosumab, met all bone mineral density (BMD) endpoints for all skeletal sites in a two-year, 332-patient Phase III study. (BioWorld Today)
Read More
Dendreon Will Fund Provenge, Other Trials with $47M Offering
Read More
TGF-Beta Gets Breast Tumors Primed for Lung Metastasis
Read More
NewCo News: SynDevRx Off to a Fast Start, with Funding and Trials Ahead
Read More
Other News To Note
Read More
Clinic Roundup
Read More